DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Subscribe To Our Newsletter & Stay Updated
